EIPICO

What EIPICO does

EIPICO (Egyptian International Pharmaceutical Industries Company), founded in 1980 in Tenth of Ramadan City, is Egypt's second-largest pharmaceutical company by value (6.4% domestic market share per IQVIA H1 2025) and the country's #1 pharmaceutical exporter, capturing 26% of Egypt's total pharmaceutical exports by value. It manufactures over 400 branded pharmaceutical products across 25 therapeutic classes — including antibiotics, ophthalmics, biosimilars, and biosimilars — across two cGMP-compliant plants covering 120,000 sqm with 53+ production lines. The company is publicly listed on the Egyptian Stock Exchange and is the largest subsidiary of ACDIMA (Arab Company for Drug Industries and Medical Appliances); Forbes Middle East has recognized it among Egypt's Top 50 Listed Companies for four consecutive years (2022-2025).

EIPICO's technology stack centers on advanced pharmaceutical manufacturing: aseptic processing with HEPA filtration (99.9997% particulate-free air) across 9 sterile areas (the largest in MENA), automatic vision inspection validated to 21 CFR Part 11 and GAMP5, closed Restricted Access Barrier Systems for penicillin/cephalosporin handling, Track & Trace serialization connected to European TraceLink/EMVO and Saudi SFDA networks, and the EIPICO 3 facility — Egypt's first modular biological and biosimilar plant using Pharmadule Morimatsu prefabricated modules and Reliance Life Sciences process technology. Vertical integration is provided through EIACO, Egypt's largest manufacturer of primary packaging materials (ampoules, vials, aluminum tubes). The company holds WHO prequalification (first in Egypt/MENA for sterile antibiotics, 2014), EU GMP, MHRA UK, SFDA, GCC, and ISO 13485/9001/14001/17025 certifications, supporting product registration across 67+ countries.

The business operates a multi-channel model: direct distribution to pharmacies and hospitals in the Egyptian domestic market (ranked #2 by value, #1 by units in ophthalmics); export to 74+ countries through local pharmaceutical importing and distributing partners; license manufacturing agreements with multinational pharmaceutical companies for local production under their brands; and semi-finished/contract manufacturing exports. The most recently completed fiscal year (2025) reported total sales of EGP 9.441 billion (+28.1% YoY), net profit of EGP 1.458 billion (+33%), and exports of USD 60.3 million. Strategic capital projects now coming online include the $100M EIPICO 3 biosimilar facility (licensed December 2025), the $165M ARAB API joint venture (groundbreaking January 2026), and a $33M pharmaceutical park in Kazakhstan — together representing approximately $300M of upstream and geographic expansion.

Name

EIPICO

Legal name

Egyptian International Pharmaceutical Industries Company (EIPICO)

Website

https://[email protected]

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

251–500 employees

Short description

Egyptian International Pharmaceutical Industries Company (EIPICO) is a publicly-listed Egyptian pharmaceutical manufacturer producing 400+ branded generics and biosimilars across 25 therapeutic classes for the Egyptian domestic market and exports to 74+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB), Pharmaceutical & Medical Plastic Packaging Manufacturing (IMANAEAK), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB), Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Biosimilar production
• Active pharmaceutical ingredients
• Sterile injectables

Headquarters

HQ city

Tenth of Ramadan City

HQ country

Egypt

HQ region

Africa

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Finished Pharmaceutical Product Sales: EIPICO manufactures and sells over 400 branded pharmaceutical products covering 25 therapeutic classes through direct distribution to pharmacies and hospitals in the Egyptian domestic market, and through distribution partners internationally.
2. License Agreements with Multinational Companies: EIPICO holds license agreements with international pharmaceutical companies to produce their products locally, generating revenue through contract manufacturing under brand licensing arrangements.
3. Semi-Finished/Contract Manufacturing Exports: EIPICO exports semi-finished contract manufacturing products and finished products under license agreement to international markets across Africa, Asia, Europe, Latin America, and CIS countries.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

EIPICO manufactures and sells over 400 branded pharmaceutical products across 25 therapeutic classes including antibiotics, antivirals, ophthalmics, cardiovasculars, analgesics, and respiratory drugs. The company operates cGMP-compliant manufacturing facilities producing tablets, capsules, sterile injectables, lyophilized powders, ophthalmics, syrups, and inhaler dosage forms, and holds the first modular biological/biosimilar manufacturing facility in Egypt and the MENA region. EIPICO also produces primary packaging materials (ampoules, vials, aluminum tubes) through affiliate EIACO and manufactures plastic eye drop bottles in-house.

Product overview

EIPICO is a leading Egyptian pharmaceutical company manufacturing over 400 pharmaceutical products covering 25+ therapeutic classes. The portfolio includes antibiotics (E-MOX, CEFOTAX, CEFOZON, EPICOCILLIN, EPICOFLOCIN, EIPICEPHEN), ophthalmic products (BRIMOSALM, BENOX, DEXATOBRIN), analgesics/antipyretics (CETAL line, Cetal Extra), corticosteroids (Dexamethasone), dermatologicals (Betaderm, EPICOGEL, EPICOMB), respiratory products (BRONCHOLIN-S, Bronchophane), cardiovasculars (ATOR), gastrointestinals (Colospasmin Forte, EPICOGEL), antivirals (COVAPRAVIR), vitamins (Cevitil), antihistamines (Brevy, Caftohist), and anthelmintics (ALZENTAL). EIPICO also operates EIPICO 3, Egypt's first modular biological and biosimilar manufacturing facility, and provides Track and Trace serialization systems. The company produces primary packaging materials through EIACO (ampoules, vials, aluminum tubes) and plastic bottles through its plastic factory.

Differentiator

Problem solved

Functional benefit

Products and services

• ADALIMAB (Adalimumab Biosimilar) Adalimumab biosimilar for treating autoimmune conditions, manufactured at EIPICO's first modular biological and biosimilar facility. Awarded supply contract to Egypt's Unified Procurement Agency (UPA).
• EIPICO 3 (Biologicals & Biosimilars Facility) First modular biological and biosimilar manufacturing facility in Egypt and Middle East. Manufactures monoclonal antibodies (mAb) and recombinant protein products from cell lines through upstream/downstream processing to finished drug products including vials, syringes, cartridges, and pens.
• EIACO Primary Packaging Materials

Quantifiable outcome

• EIPICO achieved 30% sales growth in Q1 2025, with sales exceeding EGP 1.8 billion and 2.7% market share
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• PETROJETcoreImplementation/ SI/ Consulting Partner · 14 April 2026Strategic partnership between ARAB API and PETROJET for construction and execution of the API manufacturing facility. PETROJET brings extensive capabilities in executing integrated projects across oil, gas, petrochemical, industrial, and infrastructure sectors — closely aligned with pharmaceutical and API manufacturing facility requirements.
• ARAB API Consortium (EIPICO, SCZONE, ACDIMA, NBE, Agricultural Bank of Egypt)coreStrategic or Co-development Partner · 15 January 2026Arab Active Pharmaceutical Ingredients Company (ARAB API) — first multi-purpose API factory in Egypt and Middle East. EIPICO holds ~33% stake. Consortium includes Suez Canal Economic Zone Investment Company (28.37%), ACDIMA Egypt (20.8%), National Bank of Egypt (10%), and Agricultural Bank of Egypt (8%). USD 165 million investment in Suez Canal Economic Zone, Ain Sokhna. Targets annual production of 750 tons APIs and 500 tons intermediates.
• Latvian Government (Ministry of Health)minorStrategic or Co-development Partner · 12 November 2025Latvian Minister of Health (H.E. Dr. Hosam Abu Meri) visited EIPICO factories and praised advanced manufacturing and quality assurance capabilities. Discussed cooperation opportunities given EIPICO's presence in European markets (Romania, UK) and significant product portfolio available.
• Belarusian GovernmentminorStrategic or Co-development Partner · 28 September 2025Ambassador of Belarus to Cairo (Yevgeni Sobolevski) visited EIPICO to discuss enhancing cooperation. Dr. Ahmed Kelani chairs the Egyptian-Belarusian Joint Business Council. Discussions focused on revitalizing the joint business council and preparing for the next session in Minsk.
• Al Dana Medical CompanycoreChannel Partner/ Reseller/ Distributor · 9 September 2025Strategic partnership agreement signed in Doha, Qatar in September 2025 between Dr. Ahmed Kelani and Mr. Mohammed Yousef Al Manea, Chairman of Al Dana Medical Company. Al Dana will market and distribute EIPICO's pharmaceutical products in Qatar. Qatar represents a promising market with an advanced regulatory environment and growing healthcare sector.
• Propharma Distribution CompanyminorChannel Partner/ Reseller/ Distributor · 14 July 2025Agreement signed July 2024 between Dr. Ahmed Kelani and Mr. Muzaffar Abdullah, Executive Director of Propharma Distribution Company, for distribution of EIPICO products in Uzbekistan.
• LAFZ PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 14 July 2025MOU signed between Dr. Olfat Ghorab (ACDIMA Chairman) and LAFZ Pharmaceuticals (Uzbekistan) allowing ACDIMA companies to manufacture their products at LAFZ's factory in Tashkent.
• German International University (GIU)coreStrategic or Co-development Partner · 22 October 2024MOU signed October 2024 between Dr. Ahmed Kelani and GIU President Prof. Dr. Slim Abdennadher to promote academic and industry sector cooperation aligned with education needs and job market requirements. Enables students to practice sciences with hands-on training at EIPICO facilities in the new administrative capital. Training programs for faculties of Pharmaceutical Engineering and Biotechnology lasting 5 months (equivalent to full semester). Started March 2024 with 11 students, grew to 24 students.
• Panama Ministry of HealthminorStrategic or Co-development Partner · 22 October 2024Deputy Minister of Health of Panama (Dr. Alberto Zambrano) visited EIPICO factories to explore potential cooperation to provide medicine to Panama. Visit included delegation from Egyptian Drug Authority (EDA). Dr. Alberto was impressed by EIPICO's distinguished system and performance.
• Kazakhstan Government (Ministry of Health, Kazakhstan Invest, QIC)coreStrategic or Co-development Partner · 16 September 2024EIPICO, through Egyptian-Kazakh Business Council chaired by Dr. Ahmed Kelani, is establishing the Egy Kazakh Pharmaceutical Park in Kazakhstan. Project investments of $33 million USD to create approximately 200 jobs in Almaty. Discussions with Kazakh Ministry of Health (H.E. Mrs. Akmaral Alnazarova), Kazakhstan Invest, and Qazaqstan Investment Corporation (QIC) for local pharmaceutical manufacturing to serve Kazakhstan and neighboring markets.
• Pharmadule Morimatsu AB (Sweden)coreTechnology or Integration · 1 January 2020Swedish company providing prefabricated modular structure building technique for EIPICO 3 biosimilar facility. 85 modules designed and equipped at Pharmadule's factories abroad, then shipped and installed in Egypt. Official handover ceremony July 2025. Total production area of 4,777 sqm. This modular concept ensures highest standards level and performance efficacy of EIPICO 3 production areas.
• Reliance Life Sciences (India)coreTechnology or Integration · 1 January 2020EIPICO 3 facility utilizes process standards and technology from Reliance Life Sciences — a leading manufacturer in biological/biosimilar manufacturing. Enables production of monoclonal antibodies (mAb) and recombinant protein products from cell lines through complete upstream and downstream processing.
• Egyptian Ministry of HealthcoreStrategic or Co-development Partner · 1 January 2015EIPICO participates in national health initiatives including '100 Million Healthy Lives' campaign, donating pharmaceutical products for HCV elimination, COVID-19 management, and organizing voluntary blood donation campaigns with the Ministry. Women constitute 26% of EIPICO workforce. EIPICO aligns with 12 UN Sustainable Development Goals.
• Batterjee Pharma (Batterjee Company for Pharmaceutical Products and Medical Appliances)coreStrategic or Co-development Partner · 1 January 2008EIPICO's first investment abroad — 30% stake in Batterjee Pharma established in 2008, production started 2009. Located in Jeddah Industrial Zone Phase IV on 12,000 sqm with 150+ employees. Capital raised from SAR 60M to SAR 77M. Produces 30 products exported to Bahrain, UAE, and Yemen. Dr. Ahmed Kelani serves as First Vice President representing EIPICO. Cooperation being developed under 20+ year strategic partnership for benefit of both Egyptian and Saudi pharmaceutical industries.

Scale indicators17 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Medical Union Pharmaceuticals (MUP): Egyptian pharmaceutical manufacturer in which EIPICO holds a 10% stake, producing generics across multiple therapeutic classes. Direct peer and partial insider-investor relationship with EIPICO within the Egyptian pharma landscape.
• Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical manufacturer with broad MENA footprint and significant injectable/sterile manufacturing capability. Direct comparable to EIPICO as a MENA-based branded generic manufacturer with similar therapeutic breadth and export orientation across emerging markets.
• Pharco Pharmaceuticals: Egypt's largest pharmaceutical manufacturer by domestic market share, producing branded generics across multiple therapeutic classes. Direct competitor to EIPICO in the Egyptian domestic market and on Egyptian pharmaceutical exports.
• SPIMACO Addwaeih: Saudi Arabian pharmaceutical manufacturer producing generics and branded generics across multiple therapeutic categories with MENA export reach. Closely comparable to EIPICO in regional scale, product breadth, and Gulf-oriented distribution.
• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered pharmaceutical manufacturer producing generics across multiple therapeutic classes with significant MENA and emerging-market export presence. Comparable to EIPICO in scale, regulatory certifications, and regional distribution model.
• Eva Pharma: Egyptian pharmaceutical manufacturer producing generics across antibiotics, CVS, and other therapeutic classes, with WHO GMP-certified manufacturing and exports to MENA/Africa. EIPICO's closest direct domestic competitor in the Egyptian generic pharma market.

Broad incumbents

• Cipla: Indian-headquartered global generic pharmaceutical manufacturer with broad therapeutic portfolio, large biosimilars franchise, and significant emerging-market export footprint including Africa and Middle East. Larger-scale analogue of EIPICO with similar model of affordable generics sold across emerging markets.
• Aurobindo Pharma: Indian-headquartered large-scale generic pharmaceutical and API manufacturer with strong emerging-market presence and vertically integrated operations. Comparable to EIPICO's model of affordable generics with backward integration into APIs (similar to ARAB API strategy).

Others

• ACDIMA (Arab Company for Drug Industries and Medical Appliances): Pan-Arab pharmaceutical conglomerate and EIPICO's parent organization, coordinating multiple Arab pharma manufacturers. Strategic parent and ecosystem participant providing framework for cross-Arab pharmaceutical collaboration including the ARAB API consortium.

Regional players

• Tabuk Pharmaceuticals: Saudi-headquartered pharmaceutical manufacturer producing branded generics primarily for the Saudi domestic market and selective MENA exports. Regionally comparable to EIPICO's MENA orientation though with less international export diversification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/eipico_official
• YouTubeyoutube.com/channel/UCmTcRD83a8OuTBBHzU4rA-w
• Facebookfacebook.com/EIPICO.Official
• LinkedInlinkedin.com/company/eipico
• Instagraminstagram.com/eipico.official?igshid=1r8b6bxng9d67

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EIPICO